ClinicalTrials.gg
RecruitingNCT07725406Prime REMIXUpdated Oct 26, 2026

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

A Phase 1 interventional study of Lymphodepleting chemotherapy: Cyclophosphamide and Lymphodepleting chemotherapy: Bendamustine in Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) and Relapsed or Refractory Multiple Myeloma (MM), sponsored by Weill Medical College of Cornell University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Primary conditionLymphoma, Large B-Cell, DiffuseRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Large B-Cell, Diffuse
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Lymphoma, Large B-Cell, Diffuse.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Weill Medical College of Cornell University · Phase 1, Interventional, and Treatment

How we know

Updated Oct 26, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing bendamustine in Lymphoma, Large B-Cell, Diffuse — 3 open to participants now, 5 under way, 1 of them phase 3. bendamustine · Lymphoma, Large B-Cell, Diffuse.

Planned enrollment
13th of 21
32 · median 37
Started
2026
the only one that year
Phase 1
6 of 21
1 open now
Registered
21st of 21
by date

Among the 21 studies testing bendamustine in Lymphoma, Large B-Cell, Diffuse, this one is the 13th largest by planned enrollment, is the only one that started in 2026, is one of 6 in phase 1, and was the 21st registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

3 of the 21 studies testing bendamustine in Lymphoma, Large B-Cell, Diffuse are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About bendamustine

bendamustine: first FDA approval 2008 (TREANDA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing bendamustine in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This is a clinical trial to evaluate the safety of combining CAR T-cell therapy with low-dose total body irradiation (LD-TBI) in patients with previously treated large B-cell lymphoma (LBCL) or multiple myeloma (MM). The investigators' hypothesis is that the combination will make the immune system more active in fighting cancer by increasing the display of antigens and activating pathways that lead to cell death, including death receptors like FAS and TRAIL2. This approach is expected to help the CAR T cells grow and last longer, leading to stronger anti-tumor effects and more cancer cell deaths. Participants will receive LDTBI treatment before their CAR T cell therapy and will be followed up for 2 years.

Read the detailed description

This is a single-center, open-label, non-randomized, Phase Ib trial evaluating dose escalation of low-dose total body irradiation (LD-TBI) combined with standard-of-care CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma (LBCL) or multiple myeloma (MM). The study includes two disease-specific cohorts: Cohort 1 (LBCL) receives commercial CD19-directed CAR T-cell therapy (axicabtagene ciloleucel or lisocabtagene maraleucel), and Cohort 2 (MM) receives commercial BCMA-directed CAR T-cell therapy (ciltacabtagene autoleucel). In CAR T-cell therapy, T-cells are removed via apheresis, modified to target the tumor, and infused back into the patient after lymphodepleting chemotherapy. On the same day as CAR T-cell infusion, prior to infusion, patients receive a single dose of LD-TBI.

Each cohort follows a standard 3+3 dose-escalation design (Part 1) to identify the maximum tolerated dose (MTD) across three planned dose levels (0.5 Gy, 1.0 Gy starting dose, and 2.0 Gy), based on dose-limiting toxicities occurring within 28 days of treatment. Once the MTD is identified, an expansion cohort (Part 2) of up to 10 additional participants per cohort will be randomized 1:1 to the MTD or a dose level below it to further evaluate safety and activity. Approximately 16-22 participants are anticipated per disease cohort. Participants will be followed for up to 2 years after treatment.

03

Conditions studied

  • Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
  • Relapsed or Refractory Multiple Myeloma (MM)

Browse trials for

04

In context

Lymphoma, Large B-Cell, Diffuse Reclassified

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

This study's planned enrollment of 32 is below the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Lead sponsor

Weill Medical College of Cornell University is the lead sponsor of 893 studies on the registry; 165 are open to participants now.

Of its 124 completed or terminated interventional studies of FDA-regulated products, 95 (77%) have results posted.

Compared within Lymphoma, Large B-Cell, Diffuse, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Diffuse Large B-Cell Lymphoma (DLBCL) Cohort:

  • Diagnosis of DLBCL that is to chemoimmunotherapy, relapses within 12 months of first-line chemoimmunotherapy, relapses after 12 months in a transplant-ineligible patient, or is relapsed/refractory after two or more lines of systemic therapy. Eligible histologies include DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from indolent lymphoma (follicular lymphoma, marginal zone lymphoma, or chronic lymphocytic leukemia)
  • Age ≥18 years
  • performance status ≤2
  • on PET/CT or CT per Lugano Criteria
  • Adequate organ function: ≥1000 cells/mm³; count ≥75,000 cells/mm³; or ≥45 mL/min; total ≤2.0x ; or ALT ≤3.0x ULN; >40%

For Multiple Myeloma (MM) Cohort:

  • Relapsed or refractory multiple myeloma after ≥1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, with disease refractory to lenalidomide (progression within 60 days of last lenalidomide dose)
  • Age ≥18 years
  • ECOG performance status ≤2
  • Adequate organ function: ANC ≥1000 cells/mm³; platelet count ≥75,000 cells/mm³; creatinine clearance or eGFR ≥30 mL/min; total bilirubin ≤2.0x ULN; AST or ALT ≤3.0x ULN; left ventricular ejection fraction >40%

Exclusion criteria

Exclusion Criteria:

For DLBCL Cohort:

  • History of previous total body irradiation
  • Prior CAR T-cell therapy
  • Clonal cytopenia of uncertain significance (CCUS)
  • Prior history of myeloid (MDS/AML or MPN), T-cell lymphoblastic lymphoma/leukemia, or B-cell acute lymphoblastic leukemia
  • Current or prior CNS involvement by lymphoma
  • Significant cardiovascular impairment (CHF greater than Class II, uncontrolled hypertension, unstable angina, MI or stroke within 6 months, or cardiac ventricular arrhythmia)
  • Decompensated cirrhosis
  • Active , , or infection
  • Active uncontrolled systemic fungal, bacterial, or viral infection
  • Pregnancy

For MM Cohort:

  • History of previous total body irradiation
  • History of myelodysplastic syndrome, CCUS, or concurrent active hematological malignancy with bone marrow involvement
  • Active HIV, hepatitis B, or hepatitis C infection
  • Active uncontrolled systemic fungal, bacterial, or viral infection
  • Prior CAR T-cell therapy
  • Active or history of CNS myeloma or infiltration
  • Pregnancy
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Part 1: LBCL: Dose Level -1 (0.5 Gy)

    Participants with relapsed/refractory LBCL receive lymphodepletion followed by LD-TBI 0.5 Gy on Day 0, ≥4 hours before infusion of commercial CD19-directed CAR T-cell therapy. Used if de-escalation from Dose Level 0 is required due to dose-limiting toxicity.

    Drug: Lymphodepleting chemotherapy: Cyclophosphamide · Drug: Lymphodepleting chemotherapy: Fludarabine · Other: Lisocabtagene Maraleucel · Other: Axicabtagene Ciloleucel · Radiation: Low-Dose Total Body Irradiation

  • Experimental
    Part 1: LBCL: Dose Level 0 (1.0 Gy, Starting Dose)

    Participants with relapsed/refractory LBCL receive lymphodepletion followed by LD-TBI 1.0 Gy (starting dose) on Day 0, ≥4 hours before infusion of commercial CD19-directed CAR T-cell therapy.

    Drug: Lymphodepleting chemotherapy: Cyclophosphamide · Drug: Lymphodepleting chemotherapy: Fludarabine · Other: Lisocabtagene Maraleucel · Other: Axicabtagene Ciloleucel · Radiation: Low-Dose Total Body Irradiation

  • Experimental
    Part 1: LBCL: Dose Level +1 (2.0 Gy)

    Participants with relapsed/refractory LBCL receive lymphodepletion followed by LD-TBI 2.0 Gy on Day 0, ≥4 hours before infusion of commercial CD19-directed CAR T-cell therapy. Used if Dose Level 0 is tolerated.

    Drug: Lymphodepleting chemotherapy: Cyclophosphamide · Drug: Lymphodepleting chemotherapy: Fludarabine · Other: Lisocabtagene Maraleucel · Other: Axicabtagene Ciloleucel · Radiation: Low-Dose Total Body Irradiation

  • Experimental
    Part 1: MM: Dose Level -1 (0.5 Gy)

    Participants with relapsed/refractory multiple myeloma receive lymphodepletion followed by LD-TBI 0.5 Gy on Day 0, ≥4 hours before infusion of commercial BCMA-directed CAR T-cell therapy. Used if de-escalation from Dose Level 0 is required.

    Drug: Lymphodepleting chemotherapy: Cyclophosphamide · Drug: Lymphodepleting chemotherapy: Bendamustine · Drug: Lymphodepleting chemotherapy: Fludarabine · Other: Ciltacabtagene Autoleucel · Radiation: Low-Dose Total Body Irradiation

  • Experimental
    Part 1: MM: Dose Level 0 (1.0 Gy, Starting Dose)

    Participants with relapsed/refractory multiple myeloma receive lymphodepletion followed by LD-TBI 1.0 Gy (starting dose) on Day 0, ≥4 hours before infusion of commercial BCMA-directed CAR T-cell therapy.

    Drug: Lymphodepleting chemotherapy: Cyclophosphamide · Drug: Lymphodepleting chemotherapy: Bendamustine · Drug: Lymphodepleting chemotherapy: Fludarabine · Other: Ciltacabtagene Autoleucel · Radiation: Low-Dose Total Body Irradiation

  • Experimental
    Part 1: MM: Dose Level +1 (2.0 Gy)

    Participants with relapsed/refractory multiple myeloma receive lymphodepletion followed by LD-TBI 2.0 Gy on Day 0, ≥4 hours before infusion of commercial BCMA-directed CAR T-cell therapy. Used if Dose Level 0 is tolerated.

    Drug: Lymphodepleting chemotherapy: Cyclophosphamide · Drug: Lymphodepleting chemotherapy: Bendamustine · Drug: Lymphodepleting chemotherapy: Fludarabine · Other: Ciltacabtagene Autoleucel · Radiation: Low-Dose Total Body Irradiation

  • Experimental
    Part 2: LBCL: Expansion Cohort at MTD

    Expansion-cohort participants with relapsed/refractory LBCL are randomized 1:1 to LD-TBI at the MTD or one dose level below. This arm receives LD-TBI at the MTD (single dose, Day 0), preceded by lymphodepletion and followed ≥4 hours later by commercial CD19-directed CAR T-cell therapy.

    Drug: Lymphodepleting chemotherapy: Cyclophosphamide · Drug: Lymphodepleting chemotherapy: Fludarabine · Other: Lisocabtagene Maraleucel · Other: Axicabtagene Ciloleucel · Radiation: Low-Dose Total Body Irradiation

  • Experimental
    Part 2: LBCL: Expansion Cohort Below MTD

    Expansion-cohort participants with relapsed/refractory LBCL are randomized 1:1 to LD-TBI at the MTD or one dose level below. This arm receives LD-TBI one dose level below the MTD (single dose, Day 0), preceded by lymphodepletion and followed ≥4 hours later by commercial CD19-directed CAR T-cell therapy.

    Drug: Lymphodepleting chemotherapy: Cyclophosphamide · Drug: Lymphodepleting chemotherapy: Fludarabine · Other: Lisocabtagene Maraleucel · Other: Axicabtagene Ciloleucel · Radiation: Low-Dose Total Body Irradiation

  • Experimental
    Part 2: MM: Expansion Cohort at MTD

    Expansion-cohort participants with relapsed/refractory multiple myeloma are randomized 1:1 to LD-TBI at the MTD or one dose level below. This arm receives LD-TBI at the MTD (single dose, Day 0), preceded by lymphodepletion and followed ≥4 hours later by commercial BCMA-directed CAR T-cell therapy.

    Drug: Lymphodepleting chemotherapy: Cyclophosphamide · Drug: Lymphodepleting chemotherapy: Bendamustine · Drug: Lymphodepleting chemotherapy: Fludarabine · Other: Ciltacabtagene Autoleucel · Radiation: Low-Dose Total Body Irradiation

  • Experimental
    Part 2: MM: Expansion Cohort Below MTD

    Expansion-cohort participants with relapsed/refractory multiple myeloma are randomized 1:1 to LD-TBI at the MTD or one dose level below. This arm receives LD-TBI one dose level below the MTD (single dose, Day 0), preceded by lymphodepletion and followed ≥4 hours later by commercial BCMA-directed CAR T-cell therapy.

    Drug: Lymphodepleting chemotherapy: Cyclophosphamide · Drug: Lymphodepleting chemotherapy: Bendamustine · Drug: Lymphodepleting chemotherapy: Fludarabine · Other: Ciltacabtagene Autoleucel · Radiation: Low-Dose Total Body Irradiation

Interventions

  • DrugCyclophosphamideStudies of CyclophosphamideCyclophosphamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Lymphodepleting chemotherapy given in combination with fludarabine on Days -5 to -3.

  • DrugBendamustineStudies of BendamustineBendamustine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Alternative lymphodepleting chemotherapy given on Days -5 to -4, for participants receiving ciltacabtagene autoleucel.

  • DrugFludarabineStudies of FludarabineFludarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Lymphodepleting chemotherapy given in combination with cyclophosphamide on Days -5 to -3.

  • OtherLisocabtagene Maraleucel

    Commercial CD19-directed CAR T-cell therapy administered intravenously on Day 0, at least 4 hours after completion of LD-TBI.

    Also known as: Liso-cel; Breyanzi

  • OtherAxicabtagene Ciloleucel

    Commercial CD19-directed CAR T-cell therapy administered intravenously on Day 0, at least 4 hours after completion of LD-TBI.

    Also known as: Axi-cel; Yescarta

  • OtherCiltacabtagene Autoleucel

    Commercial BCMA-directed CAR T-cell therapy administered intravenously on Day 0, at least 4 hours after completion of LD-TBI.

    Also known as: Cilta-cel; Carvykti

  • RadiationLow-Dose Total Body Irradiation

    A single dose of total body irradiation administered on Day 0, at least 4 hours before the start of CAR T-cell infusion. Dose level (0.5 Gy, 1.0 Gy, or 2.0 Gy) is determined by the assigned dose cohort.

    Also known as: LD-TBI; TBI

07

What researchers measure

Primary outcomes

  1. Incidence of Dose-Limiting Toxicities (DLTs)

    This outcome measures the number of participants experiencing a dose-limiting toxicity (DLT) at each LD-TBI dose level, within 28 days following CAR T-cell infusion. This measure is used to assess the safety and tolerability of the treatment regimen across escalating radiation dose levels and to determine the maximum tolerated dose (MTD).

    Time frame: Through Day 28 post-CAR T cell infusion

Secondary outcomes

  1. Incidence and Severity of Cytokine Release Syndrome (CRS)

    This outcome measures the number of participants experiencing CRS of any grade, and the maximum CRS grade (1-4) observed per participant, per ASTCT Consensus Criteria. This measure is used to assess the incidence and severity of this expected immune-related toxicity following combined LD-TBI and CAR T-cell therapy.

    Time frame: 12 months post-LDTBI and CAR T cell therapy combination

  2. Incidence and Severity of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

    This outcome measures the number of participants experiencing ICANS of any grade, and the maximum ICANS grade (1-4) observed per participant, per ASTCT Consensus Criteria. This measure is used to assess the incidence and severity of neurologic toxicity following combined LD-TBI and CAR T-cell therapy.

    Time frame: 12 months post-LDTBI and CAR T cell therapy combination

  3. Incidence and Severity of Immune Effector Cell-Associated Hemophagocytic Syndrome (IEC-HS)

    This outcome measures the number of participants experiencing IEC-HS of any grade, and the maximum IEC-HS grade (1-5) observed per participant, per ASTCT criteria. This measure is used to assess the incidence and severity of this rare but serious immune-related toxicity.

    Time frame: 12 months post-LDTBI and CAR T cell therapy combination

  4. Incidence of Delayed Immune Effector Cell-Associated Hematotoxicity (ICAHT)

    This outcome measures the number of participants experiencing delayed ICAHT, per EHA/EBMT consensus criteria. This measure is used to assess the incidence of prolonged blood count abnormalities following CAR T-cell therapy.

    Time frame: 12 months post-LDTBI and CAR T cell therapy combination

  5. Incidence and Severity of Treatment-Related Adverse Events

    This outcome measures the number of participants experiencing at least one treatment-related adverse event, summarized by event term and maximum CTCAE v5.0 grade (1-5) per participant. This measure is used to characterize the overall safety profile of combined LD-TBI and CAR T-cell therapy.

    Time frame: From Lymphodepletion (Day -5) through Day 360

  6. Overall Response Rate (ORR)

    This outcome measures the counts and proportion of response to treatment for participants achieving a partial response (PR), VGPR (for MM only) and complete response (CR), per Lugano Criteria (LBCL) or IMWG criteria (MM). This measure is used to estimate the preliminary anti-tumor activity of combined LD-TBI and CAR T-cell therapy.

    Time frame: At Days +30, +90, +180, and +365 post-CAR T-cell infusion

  7. Overall Survival (OS)

    This outcome measures the probability of survival over time, estimated by the Kaplan-Meier method, from start of treatment to death from any cause. This measure is used to estimate the overall survival associated with combined LD-TBI and CAR T-cell therapy.

    Time frame: 12 months post-LDTBI and CAR T cell therapy combination

  8. Progression-Free Survival (PFS)

    This outcome measures the probability of remaining free of disease progression over time, estimated by the Kaplan-Meier method, from start of treatment to disease progression or death from any cause, whichever occurs first. This measure is used to estimate the durability of disease control with combined LD-TBI and CAR T-cell therapy.

    Time frame: 12 months post-LDTBI and CAR T cell therapy combination

  9. Duration of Response (DoR)

    This outcome measures the median duration of response, estimated by the Kaplan-Meier method, from first documentation of complete or partial response until disease progression or relapse. This measure is used to estimate how durable a response to combined LD-TBI and CAR T-cell therapy is among participants who respond.

    Time frame: Assessed throughout study follow-up (up to 2 years)

  10. Adverse Event of Interest

    This outcome measures the incidence of pre-specified adverse events of interest following combined LD-TBI and CAR T-cell therapy. Adverse events of interest include parkinsonism (in participants receiving ciltacabtagene autoleucel), prolonged cytopenias, infections after Day +28, and immune effector cell-associated hemophagocytic syndrome (IEC-HS).

    Time frame: From CAR T-cell infusion (Day 0) through Day 360

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2028, 21 months later.

Of 111 non-industry phase 1 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 83. This study's planned 21 months is below that.

Counting every sponsor, half of 195 studies reached it within 53 months; a quarter within 35 and three quarters within 80.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Nov 2026, on Oct 26, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Jul 24, 2026
StartEst.
Nov 2026was Aug 2026
Primary completionEst.
Aug 1, 2028
CompletionEst.
Aug 31, 2033
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
Weill Cornell Medicine/NewYork-Presbyterian Hospital is now Recruiting
Oct 26, 2026
Start date
Aug 1, 2026→Nov 2026
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    Weill Cornell Medicine/NewYork-Presbyterian Hospital is now Recruiting
    Start date Aug 1, 2026→Nov 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07725406
Responsible party
Sponsor
First posted
Jul 24, 2026
Start date
Nov 2026 (estimated)
Primary completion
Aug 1, 2028 (estimated)
Completion
Aug 31, 2033 (estimated)
Last update
Oct 26, 2026

Study contacts

Nicole Santos, MPH
Contact
nis7058@med.cornell.edu
646-962-6827
Caitlin Gribbin, MD
Contact
ckg2001@med.cornell.edu
646-962-7950
Caitlin Gribbin, MD
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bendamustine

Start the discussion